Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

ICCC - ImmuCell Corporation Последние новости | Finranks

Home

ICCC

(ICCC)

NCM – Цена в реальном времени. Валюта: USD

6.52

-0.01 (-0.15%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

6.50

-0.02 (-0.31%)

После закрытия: Mar 27, 2026, 4:04 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Видео

No Data

There is no data to display

Пресс-релизы

ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board

ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board

PORTLAND, Maine, March 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced that Kathy Turner has been appointed to its Board of Directors, effective April 1, 2026. Ms. Turner replaces Steven Rosgen, who is retiring from the Board after serving since January 2018.

ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025

ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025

PORTLAND, Maine, March 04, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced its unaudited financial results for the year ended December 31, 2025.

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025

PORTLAND, Maine, Jan. 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced preliminary, unaudited sales results for the fourth quarter and full year of 2025.

ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®

ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®

PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity today announced that it received an Incomplete Letter from the United States Food and Drug Administration (FDA) on December 23, 2025 for its Re-Tain ® New Animal Drug Application (NADA), and simultaneously that it is increasing its First Defense ® field sales force by 50% and expanding its First Defense ® manufacturing capabilities.